Last updated: April 15, 2024
Sponsor: Surgical Innovation Associates, Inc.
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Breast Reconstruction
Treatment
DuraSorb®
Clinical Study ID
NCT04646057
19-004
Ages 22-70 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Female between the inclusive ages of 22 and 70 at the time of initial expander surgery
- Scheduled to undergo either unilateral or bilateral mastectomy with immediate 2-stagebreast reconstruction
- Is able to understand the study requirements and is willing to provide writteninformed consent
- Is willing and able to return for all scheduled study visits
Exclusion
Exclusion Criteria:
- Is pregnant or planning to become pregnant during study participation
- Has a history of failed tissue expansion or breast implantation at the intendedreconstruction site
- has a residual gross tumor at the intended reconstruction site
- has been treated for a systemic infection or a local infection at the surgical sitethat the investigator determines will affect the safety of the subject during breastreconstruction and/or mesh use
- has, as determined by the investigator, unsuitable tissue integrity for immediate 2-stage breast reconstruction
- has undergone previous radiation therapy to the reconstruction site or chest wall
- is scheduled to undergo post-operative radiation therapy at the reconstruction site
- has a Body Mass Index (BMI) < 14 or > 44
- has used nicotine products within 90 days of screening
- is currently taking medications including non-NSAID anti-coagulants,immunosuppressants (including systemic steroids), or other medications determined bythe investigator to place the subject at an increased risk of local complications ofbreast reconstruction
- has been diagnosed with a comorbid condition determined by the investigator to placethe subject at an increased risk of complications
- has participated in any other clinical study that the investigator feels may interferewith this clinical study
Study Design
Total Participants: 168
Treatment Group(s): 1
Primary Treatment: DuraSorb®
Phase:
Study Start date:
January 15, 2021
Estimated Completion Date:
December 31, 2024
Study Description
Connect with a study center
Northwestern Specialists Plastic Surgery
Chicago, Illinois 60611
United StatesSite Not Available
Northwestern University Feinberg School of Medicine
Chicago, Illinois 60611
United StatesSite Not Available
NorthShore University Health System
Evanston, Illinois 60201
United StatesSite Not Available
Harvard Brigham and Women's Faulkner Hospital
Boston, Massachusetts 02130
United StatesSite Not Available
NYU Grossman School of Medicine
New York, New York 10017
United StatesSite Not Available
Kelsey-Seybold Clinic
Houston, Texas 70725
United StatesSite Not Available
University of Wisconsin Health University Hospital
Madison, Wisconsin 53792
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.